CEBPB-high dormant tumor cells drive immune evasion via S100A8 orchestrated tumor-associated macrophages reprogramming
Theranostics · 26.02.2026 · 16 (9) · 4883-4904
DOI: 10.7150/thno.124789 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, erschienen am 26.02.2026. Verfasst von Jin Bai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, 150 Jimo Road, Pudong District, Shanghai, 200120, China. Hauptthemen laut MEDLINE: Calgranulin A, Tumor-Associated Macrophages, CCAAT-Enhancer-Binding Protein-beta, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Rationale
Triple negative breast cancer (TNBC) poorly responds to immune checkpoint blockade (ICB) therapy. Dormant tumor cells are recognized as immunotherapy-resistant reservoirs that may lead to tumor relapse, although the underlying mechanisms remain to be fully elucidated.
Methods
T cell proportions in tumors, via flow cytometry, immunohistochemistry, and multiplex immunofluorescence assays. RNA-seq and ChIP-seq were further employed to identify downstream targets of CEBPB, and ChIP-qPCR, qPCR, and Western blot were used to further validate these results.
Results
T cell infiltration. CEBPB was identified as highly expressed in dormant tumor cells, where it maintained tumor dormancy by transcriptionally activating cell cycle negative regulators, particularly CCNG2. Notably, high CEBPB expression orchestrated a tumor-supportive microenvironment with macrophage recruitment, M2 macrophage polarization, and T cell suppression. Mechanistically, S100A8 was recognized as a key transcriptional target of CEBPB to promote M2 macrophage polarization. Targeting either CEBPB or S100A8 could overcome ICB resistance and remodel the tumor microenvironment.
Conclusions
Our study demonstrate a mechanistic link between tumor dormancy and immune evasion, highlighting the CEBPB-S100A8 axis as a promising therapeutic target to potentiate ICB efficacy in TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, 150 Jimo Road, Pudong District, Shanghai, 200120, China.
- Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037, China.
- Research Center for Translational Medicine, Cancer Stem Cell Institute, Shanghai East Hospital, Tongji University School of Medicine, 150 Jimo Road, Pudong District, Shanghai, 200120, China.
- Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), and The Key Laboratory of Tumor Immunopathology, The Ministry of Education of China, C…
- Chongqing Institute of Advanced Pathology, Jinfeng Laboratory, Chongqing, 400039, China.
Zitieren
APA
Bai, J., Su, H., Wang, S., Dong, Y., & Gao, Y. (2026). CEBPB-high dormant tumor cells drive immune evasion via S100A8 orchestrated tumor-associated macrophages reprogramming. Theranostics, 16(9), 4883-4904. https://doi.org/10.7150/thno.124789
Vancouver
Bai J, Su H, Wang S, Dong Y, Gao Y. CEBPB-high dormant tumor cells drive immune evasion via S100A8 orchestrated tumor-associated macrophages reprogramming. Theranostics. 2026;16(9):4883-4904. doi:10.7150/thno.124789
BibTeX
@article{Bai2026,
author = {Bai, Jin and Su, Huilan and Wang, Shunxi and Dong, Yang and Gao, Yong},
title = {CEBPB-high dormant tumor cells drive immune evasion via S100A8 orchestrated tumor-associated macrophages reprogramming},
journal = {Theranostics},
year = {2026},
volume = {16},
number = {9},
pages = {4883--4904},
doi = {10.7150/thno.124789}
}
EUVIMED